Abstract: This document relates to methods and materials for making and using viruses (e.g., measles viruses or adenoviruses) having a reduced susceptibility to antibody neutralization (e.g., antibody neutralization by serum from measles virus vaccines). For example, recombinant morbilliviruses (e.g., recombinant measles viruses) having a modified H gene and a modified F gene, as well as methods of using a recombinant virus are provided.

Abstract: Canine distemper vims (CDV) hemagglutinin (H) and fusion (F) polypeptides are provided herein. For example, engineered configurations of CDV fusogenic membrane glycoprotein (FMG) complexes containing H and F glycoproteins are provided herein, as are pseudotyped viruses (e.g., pseudotyped lentiviruses) containing the engineered CDV FMG complexes on their surface. In addition, this document provides nucleic acid molecules encoding CDV-H and/or CDV-F polypeptide components, methods for making recombinant cells expressing the CDV-H and CDV-F polypeptides, and methods for making and using pseudotyped viruses (e.g., pseudotyped lentiviruses) containing CDV FMG complexes.

Abstract: A bactericidal and virucidal pharmaceutical composition for use on epithelial tissues such as pulmonary, nasal and oral tissues, which comprises a non-steroidal anti-inflammatory drug (NSAID) in a concentration between 5 and 500 mM and a salt, being the NSAID preferably solubilized in a hypertonic saline solution applicable in therapies for viral infections of the Herpes simplex type. The composition can be used in therapies for herpes simplex viral infections, be used as a bactericidal mouthwash, or be vehiculated to the lung by using a nebuliser, for cystic fibrosis.

Abstract: This document provides methods and materials related to CDV H and/or CDV F polypeptides. For example, CDV H polypeptides, CDV F polypeptides, recombinant viruses (e.g., vesicular stomatitis viruses (VSVs)) containing CDV H polypeptides and/or CDV F polypeptides, nucleic acid molecules encoding a CDV H polypeptide and/or CDV F polypeptide, methods for making recombinant viruses (e.g., VSVs) containing CDV H polypeptides and/or CDV F polypeptides, and methods for using recombinant viruses (e.g., VSVs) containing CDV H polypeptides and/or CDV F polypeptides to treat cancer or infectious diseases are provided.

Abstract: An electrical assembly may include a circuit board, a terminal header connected to the circuit board and including a plurality of aperture, and/or a plurality of electrical terminals connected to the terminal header. The plurality of electrical terminals may include a first electrical terminal having a first terminal configuration and/or a second electrical terminal having a second terminal configuration. The plurality of apertures may include a first aperture, a second aperture, and/or a third aperture. The first electrical terminal may include a first terminal first tail disposed at least partially in the first aperture. The second electrical terminal may include a second terminal first tail disposed at least partially in the second aperture. The second electrical terminal may include a second terminal second tail disposed at least partially in the third aperture.

Abstract: An apparatus includes a circuit board and a plurality of bus bars fixed to the circuit board. The plurality of bus bars may include a first bus bar and a second bus bar formed from adjacent portions of a bus bar wire. The first bus bar may include a first bus bar first unplated portion and the second bus bar may include a second bus bar first unplated portion. The first bus bar first unplated portion and the second bus bar first unplated portion may be formed during formation of the first bus bar.

Abstract: This document relates to methods and materials for making and using viruses (e.g., measles viruses or adenoviruses) having a reduced susceptibility to antibody neutralization (e.g., antibody neutralization by serum from measles virus vaccines). For example, recombinant morbilliviruses (e.g., recombinant measles viruses) having a modified H gene and a modified F gene, as well as methods of using a recombinant virus are provided.

Abstract: This document relates to methods and materials for making and using viruses (e.g., measles viruses or adenoviruses) having a reduced susceptibility to antibody neutralization (e.g., antibody neutralization by serum from measles virus vaccines). For example, recombinant morbilliviruses (e.g., recombinant measles viruses) having a modified H gene and a modified F gene, as well as methods of using a recombinant virus are provided.

Abstract: This document relates to methods and materials for making and using viruses (e.g., measles viruses or adenoviruses) having a reduced susceptibility to antibody neutralization (e.g., antibody neutralization by serum from measles virus vaccines). For example, recombinant morbilliviruses (e.g., recombinant measles viruses) having a modified H gene and a modified F gene, as well as methods of using a recombinant virus are provided.

Abstract: The invention relates to the use of substance P antagonists and, in particular, the use of non-peptidic NK1 receptor antagonists for the treatment of cancer and, more specifically, human melanoma, neuroblastoma, glioma, human Hodgkin's lymphoma KM-H2, lymphoblastic leukemia, human rhabdomyosarcoma, human breast carcinoma, human Burkitt's lymphoma, human lung carcinoma, human Ewing's sarcoma, human glioma and human osteosarcoma.

Abstract: The invention relates to the use of substance P antagonists and, in particular, the use of non-peptidic NK1 receptor antagonists for the treatment of cancer and, more specifically, human melanoma, neuroblastoma, glioma, human Hodgkin's lymphoma KM-H2, lymphoblastic leukemia, human rhabdomyosarcoma, human breast carcinoma, human Burkitt's lymphoma, human lung carcinoma, human Ewing's sarcoma, human glioma and human osteosarcoma.

Abstract: The invention relates to the use of substance P antagonists and, in particular, the use of non-peptidic NK1 receptor antagonists for the treatment of cancer and, more specifically, human melanoma, neuroblastoma, glioma, human Hodgkin's lymphoma KM-H2, lymphoblastic leukaemia, human rhabdomyosarcoma, human breast carcinoma, human Burkitt's lymphoma, human lung carcinoma, human Ewing's sarcoma, human glioma and human osteosarcoma.

Abstract: A battery monitoring system that may be used to measure/monitor any number of battery operating conditions, including those associated with a vehicle battery. The system may be configured to interconnect a battery post that receives energy from the battery and a cable that electrically connects the battery to a vehicle.

Abstract: Substance P antagonists and, in particular, non-peptidic NK1 receptor antagonists are useful for the treatment of cancer and, more specifically, human melanoma, neuroblastoma, glioma, human Hodgkin's lymphoma KM-H2, lymphoblastic leukemia, human rhabdomyosarcoma, human breast carcinoma, human Burkitt's lymphoma, human lung carcinoma, human Ewing's sarcoma, human glioma and human osteosarcoma.

Abstract: The invention is the addition to traditional shafts used for stand-up paddling that normally have a standard paddle at one end of the shaft and a handle at the other end of the shaft. The invention incorporates a second paddle attached to the shaft at the location of the handle. The paddle may have an interior opening surrounding a portion of the handle to enable a user to grasp the handle with a user's hand. Alternatively, the body of the paddle can be oriented at an angle relative to the handle so that a gap is formed between an interior surface of the body of the paddle and the handle so that the handle can be grasped by a user's hand with the user's fingers resting in the gap.

Abstract: The invention relates to the use of substance P antagonists and, in particular, the use of non-peptidic NK1 receptor antagonists for the treatment of cancer and, more specifically, human melanoma, neuroblastoma, glioma, human Hodgkin's lymphoma KM-H2, lymphoblastic leukaemia, human rhabdomyosarcoma, human breast carcinoma, human Burkitt's lymphoma, human lung carcinoma, human Ewing's sarcoma, human glioma and human osteosarcoma.

Abstract: Starting from a base body (1) and a cover (2) swivel-mounted thereon, enclosing inside the connector itself, wherein the cover (2) incorporates side projections (5) which, in combination with the deformable character of said cover, allow for the unlocking thereof with regard to the body, for the opening and closing thereof, the cover (2) incorporates a safety element (8) materialized in a stiff, U-shaped part, adaptable to the upper portion of the cover in correspondence with the location area of the side projections (5), such that the middle branch of said element (8) can be substantially spaced from the cover (2) in a pre-assembly position, or be adapted to said cover in the working position, in which its side branches (9) penetrate inside the cover (2), internally adapting to the side projections (5), stiffening them to make the accidental opening of the cover impossible. The safety element (8) furthermore incorporates ribs stabilizing it in both the pre-assembly position and working position.

Abstract: A multi-wire connector with interlocking device by means of which a body of the connector, provided with a plurality of first connection terminals connected to respective conductive wires, is susceptible of being fitted and interlocked in a cavity of a base piece provided with other such second connection terminals provided for coupling with said first connection terminals.

Abstract: A moveable on-site harvesting/packing plant is built on a framework comprising a floor area and table area elevated above and extending transversely over rows of crop to be harvested such that the table area is to the rear of the moveable plant as it is towed along the crop rows. Pickers follow the moveable plant as it is towed and place harvested produce onto the table area. Extending transversely outboard from either end of the table area are inclined transverse wings, upon which harvested produce is placed and rolls onto the table area. Outboard of the table area on platforms are box assemblers who assemble boxes from stacks of flat cartons, sliding the assembled boxes along an overhead box rack toward the center of the packing table. In front of the packing table, standing on the floor area, are packers who take the empty, assembled boxes from the overhead box rack and place them into box supports which hang from the front of the packing table.